Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Analysis of Isotope Imbalance May Aid Liver Cancer Diagnosis

By LabMedica International staff writers
Posted on 01 Mar 2015
A novel approach for diagnosing liver cancer (hepatocellular carcinoma) is based on analytical methods frequently used in the earth sciences.

Hepatocellular carcinoma (HCC) is the most common type of liver cancer. More...
Most cases of HCC are secondary to either a viral hepatitis infection (hepatitis B or C) or cirrhosis (alcoholism being the most common cause). Compared to other cancers, HCC is a rare tumor in the United States. In countries where hepatitis is not endemic, most malignant cancers in the liver are not primary HCC but metastasis of cancer from elsewhere in the body.

Investigators at the École Normale Supérieure de Lyon (France) analyzed the ratios of stable copper (Cu) and sulfur (S) isotopes in liver cancer patients. This study was a hi-tech look into observations dating from as far back as 1928 indicating that the hypoxic tumor environment altered the normal metabolism of elements such as copper and sulfur as well as the redox state of the metals, impacting their ability to bind to ligands.

Specifically, the investigators used the stable isotope compositions of copper (65Cu/63Cu) and sulfur (34S/32S) in the blood of patients with (HCC) as a tool to explore cancer-driven copper and sulfur imbalances.

They reported that copper was 63Cu-enriched by about 0.4% and sulfur was 32S-enriched by about 1.5% in the blood of patients compared with that of control subjects. HCC patients had more copper in red blood cells and serum compared with control subjects. However, the isotopic signature of this blood extra copper burden was not in favor of a dietary origin but rather suggested a reallocation in the body of copper bound to cysteine-rich proteins such as metallothioneins. The magnitude of the sulfur isotope effect was similar in red blood cells and serum of HCC patients, implying that sulfur fractionation was systemic. The 32S-enrichment of sulfur in the blood of HCC patients was compatible with the notion that sulfur partly originated from tumor-derived sulfides.

First author Dr. Vincent Balter, professor of geology at the École Normale Supérieure de Lyon, said, "This indicates that the blood 65Cu levels would decrease as a function of the severity of the cancer, which would be of interest for the estimation of tumor burden. The enrichment of blood with the 32S isotope may provide new biomarkers for cancer detection and monitoring."

The study was published in the January 27, 2015, issue of the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS).

Related Links:

École Normale Supérieure de Lyon



Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Collection and Transport System
PurSafe Plus®
ESR Analyzer
TEST1 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.